Filing Flows › vTv Therapeutics (VTVT) › Stock forecast & fair value
vTv Therapeutics (VTVT) stock forecast and price target
vTv Therapeutics (VTVT) trades at $21.03. 7 analysts' median price target is $57.00 (+171%), from $42.00 to $67.00.
vTv Therapeutics' latest quarter
vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%, net earnings $24.1M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for VTVT stock?
The median of 7 analysts' 12-month targets is $57.00, +171% from $21.03; the range is $42.00 to $67.00. The average rating is none.
Does vTv Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is VTVT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.